NCT01669239CompletedPhase 2
OptiHER-Heart: A Prospective, Multicenter, Single-arm, Phase II Study to Evaluate the Safety of Neoadjuvant Liposomal Doxorubicin (Myocet®) Plus Paclitaxel, Trastuzumab, and Pertuzumab in Patients With HER2-positive Breast Cancer
SOLTI Breast Cancer Research Group19 sites in 1 country83 target enrollmentStarted: June 2013Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 83
- Locations
- 19
- Primary Endpoint
- Rate of symptomatic (type A) and asymptomatic (type B) cardiac events during the study treatment period
Study Overview
Brief Summary
This is a prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 74 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Written informed consent for all study procedures according to local regulatory requirements prior to beginning specific protocol procedures
- •Female patients
- •Age 18-74 years
- •ECOG Performance Status of 0 or 1
- •Histologically confirmed, untreated, invasive breast carcinoma stage II-IIIB
- •Tumor size > 2 cm by clinical or radiological assessment
- •HER2+ invasive BC according to ASCO/CAP guidelines
- •Known hormone receptor status or the possibility of its assessment
- •Adequate organ function defined as:
- •Absolute Neutrophil Count (ANC) ≥ 1.5 x 10**9/L
- •Hemoglobin (Hgb) ≥ 9 g/dL
- •Platelets > 100 x 10**9/L
- •Creatinine ≤ 1.6 mg/dL
- •ALT and AST ≤ 2.5 x ULN
- •Alkaline phosphatase ≤ 5 ULN
- •Total bilirubin ≤ 1.5 mg/dL
- •Baseline LVEF ≥ 55% measured by echocardiogram or MUGA scan
- •Negative β-HCG pregnancy test (serum) for premenopausal women of reproductive capacity (those who are biologically capable of having children) and for women less than 12 months after the menopause. All subjects who are biologically capable of having children must agree and commit to the use of a reliable method of birth control from 2 weeks before administration of the first dose of investigational product until 28 days after the last dose of investigational product
- •Absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
Exclusion Criteria
- •Clinical or radiologic evidence of metastatic disease at the time of study entry
- •Prior chemotherapy, radiotherapy, or surgery for BC, other than excision of a tumor in the contralateral breast, and provided that the patient did not previously receive adjuvant radiotherapy or chemotherapy
- •Subjects with a concurrently active second malignancy, other than adequately treated non melanoma skin cancers, in situ melanoma or in situ cervical cancer. Subjects with other non-mammary malignancies must have been disease-free for at least 5 years
- •Known or suspected hypersensitivity reaction to any investigational or therapeutic compound or their incorporated substances
- •Presence of CHF or LVEF < 55%
- •Clinically significant (i.e. active) cardiovascular disease, including cerebrovascular accident (< 6 months before enrollment), unstable angina pectoris, myocardial infarction ≤ 6 months before enrollment, uncontrolled hypertension (systolic > 150 mmHg and/or diastolic > 100 mmHg), or high-risk uncontrolled arrhythmias
- •Uncontrolled diabetes mellitus, active peptic ulcer disease, or uncontrolled epilepsy
- •Active uncontrolled infection at the time of enrolment
- •History of significant co-morbidities that, in the judgment of the investigator, may interfere with the conduction of the study, the evaluation of response, or with informed consent
- •Use of any investigational agent or participation in another therapeutic clinical trial concurrently or in the previous 30 days before the enrollment
- •Patients who are pregnant or breast-feeding
- •Women of child-bearing potential who are unable or unwilling to use acceptable contraceptive measures
- •Inability or unwillingness to abide by the study protocol or cooperate fully with the investigator or designee
Arms & Interventions
Liposomal Doxorubicin
Experimental
Six cycles of:
- Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks
- Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks
- Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks
- Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks
Intervention: Liposomal Doxorubicin (Drug)
Outcomes
Primary Outcomes
Rate of symptomatic (type A) and asymptomatic (type B) cardiac events during the study treatment period
Time Frame: Following 12 months after first dose of the study treatment
Secondary Outcomes
- pCR in breast (pCRB)(At the time of definitive surgery, an expected average of 23 weeks)
- Breast conservation rate at surgery(At the time of definitive surgery, an expected average of 23 weeks)
- Evaluation of serum biomarkers predictive of cardiotoxicity(Following 12 months after first dose of the study treatment)
- Residual Cancer Burden (RCB) at surgery following the procedures of the MD Anderson Cancer Center(At the time of definitive surgery, an expected average of 23 weeks)
- Dose reductions due to treatment toxicity (assessed by CTCAE v.4)(Following 12 months after first dose of the study treatment)
- Number of patients with adverse events and serious adverse events (assessed by CTCAE v.4)(Following 12 months after first dose of the study treatment)
- Clinical objective response rate (cORR) in the breast and axilla by RECIST criteria version 1.1(At the time of definitive surgery, an expected average of 23 weeks)
- Time of onset and time of recovery from symptomatic (type A) and asymptomatic (type B) cardiac events (assessed by CTCAE v.4)(Following 12 months after first dose of the study treatment)
- Dose delays due to treatment toxicity (assessed by CTCAE v.4)(Following 12 months after first dose of the study treatment)
- pCR in breast and axilla (pCRBA)(At the time of definitive surgery, an expected average of 23 weeks)
- Percentage of patients with grade 3/4 neutropenia (assessed by CTCAE v.4)(Following 12 months after first dose of the study treatment)
Investigators
Study Sites (19)
Loading locations...
Similar Trials
Recruiting
Phase 2
A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal CancerRectal CancerNCT05939661Osaka University45
Completed
Phase 2
Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIentsMetastatic Thymic CarcinomaThymoma Type B3NCT04710628MedSIR43
Recruiting
Phase 2
HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasPlexiform NeurofibromasNeurofibromatosis 1NCT05331105Shanghai Kechow Pharma, Inc.70
Unknown
Phase 2
Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic CancerBorderline Resectable Pancreatic CancerNCT03850769Peking Union Medical College Hospital60
Unknown
Phase 2
A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)Triple Negative Breast CancerNCT05068141CSPC ZhongQi Pharmaceutical Technology Co., Ltd.79